Anti-egfr antibody drug conjugate formulations

Anti-egfr antibody drug conjugate formulations

Discloses lyophilized pharmaceutical formualtions comprising an anti-EGFR antibody drug conjugate (ADC). The antibody has the HCDR sequences of SEQ ID NO: 15-17 and the LCDRs of SEQ ID NO: 20-22 or the HCVR of SEQ ID NO: 13 and the LCVR of SEQ ID NO: 18. The auristatin can be monomethylauristatin F...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Markus Tschoepe, Katharina Kaleta, Vineet Kumar
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Discloses lyophilized pharmaceutical formualtions comprising an anti-EGFR antibody drug conjugate (ADC). The antibody has the HCDR sequences of SEQ ID NO: 15-17 and the LCDRs of SEQ ID NO: 20-22 or the HCVR of SEQ ID NO: 13 and the LCVR of SEQ ID NO: 18. The auristatin can be monomethylauristatin F (MMAF). The formulation further comprises a sugar, histidine and a surfactant. In a further embodiment the formulation comprises sucrose, histidine and polysorbate 80.